Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Sapanisertib
Другие языки:

    Sapanisertib

    Подписчиков: 0, рейтинг: 0
    Sapanisertib
    Sapanisertib.svg
    Identifiers
    • 5-(4-Amino-1-propan-2-ylpyrazolo[3,4-d]pyrimidin-3-yl)-1,3-benzoxazol-2-amine
    CAS Number
    PubChem CID
    UNII
    KEGG
    Chemical and physical data
    Formula C15H15N7O
    Molar mass 309.333 g·mol−1
    3D model (JSmol)
    • CC(C)N1C2=C(C(=N1)C3=CC4=C(C=C3)OC(=N4)N)C(=NC=N2)N
    • InChI=1S/C15H15N7O/c1-7(2)22-14-11(13(16)18-6-19-14)12(21-22)8-3-4-10-9(5-8)20-15(17)23-10/h3-7H,1-2H3,(H2,17,20)(H2,16,18,19)
    • Key:GYLDXIAOMVERTK-UHFFFAOYSA-N

    Sapanisertib (also known as MLN0128, INK128 and TAK-228) is an experimental small molecule inhibitor of mTOR which is administered orally. It targets both mTORC1 and mTORC2.

    Developed by Millennium Pharmaceuticals, and is in phase II clinical trials for breast cancer, endometrial cancer, glioblastoma, renal cell carcinoma, and thyroid cancer. The drug has been well tolerated by patients with advanced solid tumours in Phase I trials.


    Новое сообщение